Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5)

Current Topics in Medicinal Chemistry

Volumn 5, Issue 9, 2005, Pages 825-846

  Williams Jr , David L ^a   Lindsley, Craig W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Metabotropic glutamate receptors; mGluR5; NMDA hypofunction; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 CYANO(1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3,3' DIFLUOROBENZALDAZINE; 3,5 DIHYDROXYPHENYLGLYCINE; 4 CARBOXY 3 HYDROXYPHENYLGLYCINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; [4 CHLORO 2 [(1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)METHYL]PHENYL] 2 HYDROXYBENZAMIDE; AMPHETAMINE; BAY 367620; BENZAMIDE DERIVATIVE; DIMETHYL SULFOXIDE; GLUTAMATE RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NPS 2390; NPS 23909; PHOSPHOTRANSFERASE INHIBITOR; PURINE RECEPTOR; PYRAZOLE DERIVATIVE; QUISQUALIC ACID; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; CHO CELL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DOSE RESPONSE; DOWN REGULATION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IC 50; IN VITRO STUDY; MATHEMATICAL MODEL; NEUROTOXICITY; NONHUMAN; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TACHYPHYLAXIS;

ALLOSTERIC REGULATION; ANIMALS; BENZALDEHYDES; BENZAMIDES; DRUG DESIGN; EXCITATORY AMINO ACID AGONISTS; HUMANS; HYDRAZONES; PYRAZOLES; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24644520313     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054750290     Document Type: Review

References (45)

1. Johnson, M.P.; Nisenbaum, E.S.; Large, T.H.; Emkey, R.; Baez, M.; Kingston, A.E. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem. Soc. Trans. 2004, 32, 881-887.
2. Kew, J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Therap. 2004, 104, 233-244.
3. Kew, J.N.C.; Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005, 179, 4-29.
4. O'Hara, P.J.; Sheppard, P.O.; Thogerson, H.; Venezia, D.; Haldeman, B.A.; McGrane, V.; Houamed, K.M.; Thomsen, C.; Gilbert, T.L.; Mulvihill, E.R. The ligand-binding d omain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993, 11, 41-52.
5. Conn, P.J.; Pin, J-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
6. Bockaert, J.; Pin, J-P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J., 1999, 18, 1723-1729.
7. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148, 1301-1308.
8. Olney, J.W.; Newcomer, J.W.; Farber, N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatry Res. 1999, 33, 523-533.
9. Javitt, D.C.; Zylberman, I.; Zukin, S.R.; Heresco-Ley, U.; Lindenmayer, J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 1994, 151, 1234-1236.
10. Goff, D.C.; Tsai, G.; Manoach, D.S.; Coyle, J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 1995, 152, 1213-1215.
11. Heresco-Levy, U.; Javitt, D.; Ermilov, M.; Mordel, C.; Horowitz, A.; Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 1996, 169, 610-617.
12. Heresco-Levy, U.; Javitt, D.; Ermilov, M.; Mordel, C.; Silipo, G; Lichenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999, 56, 29-36.
13. Heresco-Levy, U.; Ermilov, M.; Shimoni, J; Shapira, B; Silipo, G.; Javitt, D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 2002, 159, 480-482.
14. Tsai, G.; Yang, P.; Chung, L-C.; Lange, N.; Coyle, J. D-serine added to antipsychotics for he treatment of schizophrenia. Biol. Psychiatry 1998, 44, 1081-1089.
15. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P.J. Metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20, 7871-7879.
16. Mannaioni, G.; Marino, M.J.; Valenti, O.; Traynelis, S.F.; Conn, P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci. 2001, 21, 5925-5934.
17. Pisani, A.; Gubellini, P.; Bonsi, P.; Conquet, F.; Picconi, B.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106, 579-587.
18. Benquet, P.; Gee, C.E.; Gerber, U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J. Neurosci. 2002, 22:9679-9686.
19. Pisani, A.; Calabresi, P.; Centonze, D.; Bernardi, G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurons. Br. J. Pharmacol. 1997, 120, 1007-1014.
20. Kinney, G.G.; Burno, M.; Campbell, U.C.; Hernandez, L.M.; Rodriguez, D.; Bristow, L.J.; Conn, P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Therapeut. 2003, 306, 116-123.
21. Chavez-Noriega, L.E.; Schaffhauser, H.J.L.; Campbell, U.C. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1, 261-281.
22. Marino, M.J.; Conn, P.J. Direct and indirect modulation of the N-methyl-D-aspartate receptor: potential for the development of novel antipsychotic therapies. Curr. Drug Targets CNS Neurol. Disord. 2002, 1, 1-19.
23. Moghaddam, B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia Psychopharmacol 2004, 174, 39-44.
24. Schoepp, D.D.; Jane, D.E.; Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
25. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Disc. 2002, 1, 198-210.
26. van Wagenen, B.; Artman, L.; Hammerland, L.; Hung, B.; Johnson, J.; Krapcho, K.; Levinthal, C.; Logan, M.; Moe, S.; Mueller, A.; Simin, R.; Smith, D.; Storjohann, L.; Stormann, T. In vitro pharmacological characterizations of NPS2390: a highly potent and selective, non-competitive antagonist of group-I metabotropic glutamate receptors. Soc. Neurosci. Abstr. 1998, 24, 576.
27. Varney, M.A.; Cosford, N.D.P.; Jachec, C.; Rao, S.P.; Sacaan, A.; Lin, F-F.; Bleicher, L.; Santori, E.M.; Flor, P.J.; Allgeier, H.; Gasparini, F.; Kuhn, R.; Hess, S.D.; Veliçelebi, G.; Johnson, E.C. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Therapeut. 1999, 290, 170-181.
28. Gasparini, F.; Lingenhöhl, K.; Stoehr, N.; Flor, P.J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M.A.; Johnson, E.C.; Hess, S.D.; Rao, S.P.; Sacaan, A.I.; Santori, E.M.; Gönul, V.; Kuhn, R. (2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38, 1493-1503.
29. Litschig, S.; Gasparini, F.; Rüegg, D.; Stoehr, N.; Flor, P.J.; Vranesic, I.; Prezeau, L.; Pin, J-P.; Thomsen, C.; Kuhn, R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 1999, 55, 453-461.
30. Annoura, H.; Fukunaga, A.; Uesugi, M.; Tatsuoka, T.; Horikawa, Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cycloprop[b] chromen-1a-caroxylates. Bioorgan. Med. Chem. Lett. 1996, 6, 763-766.
31. Carroll, F.Y.; Stolle, A.; Beart, P.M.; Voerste, A.; Brabet, I.; Mauler, F.; Joly, C.; Antonicek, H.; Bockaert, J.; Müller, T.; Pin, J-P.; Prezeau, L. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 2001, 59, 965-973.
32. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 2003, 13, 351-354.
33. Cosford, N.D.P.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N.D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M.A. 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46, 204-206.
34. Malherbe, P.; Kratochwil, N.; Knoflach, F.; Zenner, M-T.; Kew, J.N.C.; Kratzeisen, C.; Maerki, H.P.; Adam, G. Mutel, V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 2003, 278, 8340-8347.
35. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol. 2003, 63, 1082-1093.
36. Knoflach, F.; Mutel, V.; Jolidon, S.; Kew, J.N.C.; Malherbe, P.; Vieira, E.; Wichmann, J.; Kemp, J.A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc. Natl. Acad. Sci. USA 2001, 98, 13402-13407.
37. O'Brien, J.A.; Lemaire, W.; Chen, T-B.; Chang, R.S.L.; Jacobson, M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Mol. Pharmacol. 2003, 64, 731-740.
38. O'Brien, J.A.; Lemaire, W.; Wittmann, M.; Jacobson, M.A.; Ha, S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J.; Rowe, B. Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. Jr. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J. Pharmacol. Exp. Therapeut. 2004, 309, 568-577.
39. Kinney, G.G.; O'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J.; Clements, M.K.; Chen, T-B.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L.Jr. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Therapeut. 2005, 313, 199-206.
40. Lindsley, C.W.; Wisnoski, D.D.; Duggan, M.E.; Leister, W.H.; Hartman, G.D. Huff, J.R.; Williams, D.L.Jr.; O'Brien, J.A.; Lemaire, W.; Sur, C.; Pettibone, D.J.; Kinney, G.G.; Burno, M.; Tiller, P.R.; Smith, S. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 (mGluR5) that potentiate receptor function in vivo. J. Med. Chem. 2004, 47, 5825-5828.
41. Parmentier, M-L.; Prézeau, L.; Bockaert, J.; Pin, J-P. A model for the functioning of family 3 GPCRs Trends Pharmacol. Sci. 2003, 23, 268-274.
42. Hall, D.A. (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 2000, 58, 1412-1423. Erratum: Mol. Pharmacol. 2001, 59, 161.
43. Christopoulos, A. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 1998, 19, 351-357.
44. Goudet, C.; Gaven, F.; Kniazeff, J.; Vol, C.; Liu, J.; Cohen-Gonsaud, M.; Acher, F.; Prézeau, L.; Pin, J.P. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl. Acad. Sci. USA 2004, 101, 378-383.
45. Bessis, A-S.; Bonnet, B.; Le Poul, E.; Rocher, J-P.; Epping-Jordan, M. Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5). WO 044797, 2005, pp. 141.